LUPIN2025-07-012025-09-30LUPIN2025-09-30LUPIN2025-03-31LUPIN2025-04-012025-09-30LUPIN2025-07-012025-09-30in-capmkt:OtherExpenses1MemberLUPIN2025-07-012025-09-30in-capmkt:OtherExpenses2MemberLUPIN2025-04-012025-09-30in-capmkt:OtherExpenses1MemberLUPIN2025-04-012025-09-30in-capmkt:OtherExpenses2MemberLUPIN2025-07-012025-09-30in-capmkt:ReportableSegments1MemberLUPIN2025-07-012025-09-30in-capmkt:ReportableSegments2MemberLUPIN2025-07-012025-09-30in-capmkt:ReportableSegments3MemberLUPIN2025-04-012025-09-30in-capmkt:ReportableSegments1MemberLUPIN2025-04-012025-09-30in-capmkt:ReportableSegments2MemberLUPIN2025-04-012025-09-30in-capmkt:ReportableSegments3MemberLUPIN2025-07-012025-09-30in-capmkt:ReportableSegments1MemberLUPIN2025-07-012025-09-30in-capmkt:ReportableSegments2MemberLUPIN2025-07-012025-09-30in-capmkt:ReportableSegments3MemberLUPIN2025-04-012025-09-30in-capmkt:ReportableSegments1MemberLUPIN2025-04-012025-09-30in-capmkt:ReportableSegments2MemberLUPIN2025-04-012025-09-30in-capmkt:ReportableSegments3MemberLUPIN2025-07-012025-09-30in-capmkt:ReportableSegments1MemberLUPIN2025-09-30in-capmkt:ReportableSegments1MemberLUPIN2025-07-012025-09-30in-capmkt:ReportableSegments2MemberLUPIN2025-09-30in-capmkt:ReportableSegments2MemberLUPIN2025-07-012025-09-30in-capmkt:ReportableSegments3MemberLUPIN2025-09-30in-capmkt:ReportableSegments3MemberLUPIN2025-07-012025-09-30in-capmkt:ReportableSegments1MemberLUPIN2025-09-30in-capmkt:ReportableSegments1MemberLUPIN2025-07-012025-09-30in-capmkt:ReportableSegments2MemberLUPIN2025-09-30in-capmkt:ReportableSegments2MemberLUPIN2025-07-012025-09-30in-capmkt:ReportableSegments3MemberLUPIN2025-09-30in-capmkt:ReportableSegments3MemberLUPIN2025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1LUPIN2025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1LUPIN2025-07-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss1LUPIN2025-04-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares500257LUPINNOTLISTEDINE326A01037Lupin LimitedMain BoardEquity2025-04-012026-03-312025-11-062025-10-22INRMillionsQuarterlySecond quarterMulti segment2025-11-0613:00:002025-11-0618:05:00trueCash Flow IndirectNot applicable2025-07-012025-09-30UnauditedConsolidated7047510000090000000071375100000113915000007249200000-39300000011055600000107590000031677000001775850000051305400000200697000000200697000003239900000198150000052214000000148483000000000148483000009582000001580650000014779200000691000001573490000071600000913600000232.3632.280032.3632.281. The above Consolidated Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on November 06 2025. The Statutory Auditors of the Company have carried out limited review of the above Consolidated Financial Results pursuant to Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015. <BR> <BR> 2. The Consolidated Financial Results include the financial results of the subsidiaries Lupin Pharmaceuticals Inc. U.S.A. Lupin Australia Pty Limited Australia Nanomi B.V. Netherlands Pharma Dynamics Proprietary Limited South Africa Hormosan Pharma GmbH Germany Multicare Pharmaceuticals Philippines Inc. Philippines Lupin Atlantis Holdings SA Switzerland Lupin Healthcare UK Limited U.K. Lupin Pharma Canada Limited Canada Generic Health Pty Limited Australia Lupin Mexico S.A. de C.V. Mexico Lupin Philippines Inc. Philippines Lupin Diagnostics Limited India Generic Health SDN. BHD. Malaysia Lupin Inc. U.S.A. Laboratorios Grin S.A. de C.V. Mexico Medquimica Industria Farmaceutica LTDA Brazil Novel Laboratories Inc. U.S.A. Lupin Research Inc. U.S.A. Lupin Management Inc. U.S.A Lupin Europe GmbH Germany Lupin Biologics Limited India Lupin Oncology Inc. U.S.A Lupin Digital Health Limited India Avenue Coral Springs LLC U.S.A. Southern Cross Pharma Pty Ltd Australia Lupin Life Sciences Limited India formerly known as Lupin Atharv Ability Limited India Lupin Manufacturing Solutions Limited India Medisol S.A.S. France Lupin Lanka Private Ltd. Sri Lanka w.e.f. August 05 2024 Lupin NZ Ltd. New Zealand w.e.f. August 08 2024 Lupinlife Consumer Healthcare Limited India w.e.f. March 08 2025 Renascience Pharma Limited U.K. w.e.f. April 02 2025 and a joint venture YL Biologics Limited Japan. <BR> <BR> 3. The Consolidated Financial Statements are prepared in accordance with Ind AS 110 Consolidated Financial Statements and Ind AS 28 Investments in Associates and Joint Ventures. <BR> <BR> 4. During the quarter ended September 30 2025 41745 year to date 192823 equity shares of Rs. 2 each fully paid up were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans ESOPs resulting in an increase in the paid up share capital by Rs. 0.1 million year to date Rs. 0.4 million and securities premium account by Rs. 69.5 million year to date Rs. 215.6 million. <BR> <BR> 5. During the quarter ended September 30 2025 the Company through its wholly owned subsidiary Nanomi B.V. Netherlands Nanomi has entered into a definitive agreement to acquire 100% share capital of VISUfarma B.V. Netherlands for a consideration of Euro 190.0 million subject to closing adjustments. Pending regulatory approval no impact has been given in the results. The acquisition related costs are accounted in Other expenses. <BR> <BR> 6. During the quarter ended June 30 2025 the Company through its wholly owned step down subsidiary Lupin Healthcare UK Limited U.K. acquired 100% equity share capital of Renascience Pharma Limited U.K. for a consideration of Rs. 1361.6 million GBP 12.3 million. Fair value of intangibles acquired Rs. 1239.4 million deferred tax liability Rs. 309.8 million Goodwill Rs. 325.9 million has been accounted based on report of independent valuer. <BR> <BR> 7. As approved by the Members of the Company at the 43rd Annual General Meeting held on August 11 2025 the Company has disbursed on August 14 2025 a final dividend of Rs. 12 per equity share of the face value of Rs. 2 each aggregating <BR> Rs. 5481.0 million. <BR> <BR> 8. During the quarter six months ended September 30 2024 and year ended March 31 2025 the Group has made a provision of Rs. 585.1 million and Rs. 1441.2 million respectively towards ongoing disputes. <BR> <BR> 9. During the six months ended September 30 2024 and year ended March 31 2025 Lupin Limited and its subsidiary agreed to settle the dispute for an amount of USD 9.0 million Rs.750.5 million in connection with the drug Glumetza® without admitting any liability for any wrongdoing with a view to avoid the costs and uncertainties of continued litigation. <BR> <BR> 10. During the year ended March 31 2025 the Group has recognised an impairment charge of Rs 1209.0 million related to certain property plant and equipment capital work in progress intangible assets intangible assets under development and goodwill. <BR> 2025-04-012025-09-30UnauditedConsolidated13315850000016904000001348489000002265780000014388700000-1079500000218856000001993500000615750000034620200000100623800000342251000000342251000008148800000-9866000007162200000027062900000000027062900000256040000029623300000269695000009340000029507900000115400000913600000259.0558.90059.0558.9Other expenses19795800000Net (gain) / loss on foreign currency transactions-2037300000Other expenses37516200000Net (gain) / loss on foreign currency transactions-289600000052555700000592860000002474920000023629300000158920000002928000005958000000285000001324340000013867700000672630000030064000001323452000005954960000032418700000629015000001327580000017126400000483000005668200000131438900000286800000113839000002026592000000033500440000091360000019541230000019632590000095780000019728370000015390100000000382760000019217700000485670000025593000000288100000029514700000423945000001191500000328800000003407150000089211000008538710000013488100000278570000065451000000108206000000001377207000003350044000001 Property Plant and Equipment includes Right of use Assets of Rs 5057.0 mn. <BR> 2 Other Non current Assets includes Non current tax assets of Rs. 475.6 mn. <BR> 3 Other Non current financial liabilities includes Lease liabilities of Rs. 3058.6 mn. <BR> 4 Other Current Financial Liabilities includes lease liabilities of Rs. 1326.8 mn.Pharmaceuticals70103200000Others376800000Less: Inter segment0Pharmaceuticals132467300000Others699600000Less: Inter segment0704800000001331669000004900000840000070475100000133158500000Pharmaceuticals20479900000Others-410200000Less: Inter segment0Pharmaceuticals35058300000Others-833200000Less: Inter segment020069700000342251000002006970000034225100000Pharmaceuticals332471500000Others2555200000Less: Inter segment-223000003350044000000335004400000Pharmaceuticals136746500000Others995200000Less: Inter segment-2100000013772070000001377207000001993500000-4580800000-642840000001166000000-668300000162400000-2334800000-11396000004004400000020589000008299000006157500000048100000285700000300800000214300000-183500000001083200000234700000-3451000000-25270000008185000000-3932000003383190000000059436000000278883000000135750000000000095700000573800000000000000000000000010672000000-21350300000-27282900000000000534000000487410000003819000005476500000183560000000-2766500000-21611000000-21611000001543690000013275800000Items that will not be reclassified subsequently to profit or loss9370000093700000Items that will not be reclassified subsequently to profit or loss-9800000-9800000428000006600000Items that will be reclassified subsequently to profit or loss754300000754300000Items that will be reclassified subsequently to profit or loss24492000002449200000-153000000-1276000009582000002560400000